Table 2 Number and proportion of signals for Con-DOX and Lip-DOX at the SOC level in FAERS. (SOC, System Organ Classes; Con-DOX, conventional doxorubicin; Lip-DOX, liposomal doxorubicin.).
SOC | Con-DOX | Lip-DOX | ||
|---|---|---|---|---|
Signals, n | Proportion,% | Signals, n | Proportion,% | |
Infections and infestations | 77 | 17.95% | 58 | 17.42% |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 44 | 10.26% | 59 | 17.72% |
Cardiac disorders | 40 | 9.32% | 27 | 8.11% |
Gastrointestinal disorders | 33 | 7.69% | 17 | 5.11% |
Respiratory, thoracic and mediastinal disorders | 30 | 6.99% | 16 | 4.80% |
Blood and lymphatic system disorders | 23 | 5.36% | 16 | 4.80% |
Hepatobiliary disorders | 21 | 4.90% | 7 | 2.10% |
General disorders and administration site conditions | 19 | 4.43% | 16 | 4.80% |
Nervous system disorders | 18 | 4.20% | 11 | 3.30% |
Metabolism and nutrition disorders | 18 | 4.20% | 19 | 5.71% |
Injury, poisoning and procedural complications | 15 | 3.50% | 12 | 3.60% |
Investigations | 15 | 3.50% | 24 | 7.21% |
Vascular disorders | 11 | 2.56% | 7 | 2.10% |
Skin and subcutaneous tissue disorders | 10 | 2.33% | 12 | 3.60% |
Pregnancy, puerperium and perinatal conditions | 10 | 2.33% | 5 | 1.50% |
Endocrine disorders | 8 | 1.86% | 1 | 0.30% |
Renal and urinary disorders | 7 | 1.63% | 7 | 2.10% |
Immune system disorders | 7 | 1.63% | 7 | 2.10% |
Congenital, familial and genetic disorders | 5 | 1.17% | 4 | 1.20% |
Reproductive system and breast disorders | 4 | 0.93% | 3 | 0.90% |
Product issues | 4 | 0.93% | 1 | 0.30% |
Eye disorders | 3 | 0.70% | 0 | 0.00% |
Musculoskeletal and connective tissue disorders | 2 | 0.47% | 1 | 0.30% |
Psychiatric disorders | 2 | 0.47% | 0 | 0.00% |
Ear and labyrinth disorders | 2 | 0.47% | 1 | 0.30% |
Surgical and medical procedures | 1 | 0.23% | 2 | 0.60% |
Social circumstances | 0 | 0.00% | 0 | 0.00% |
Total | 429 | 100.00% | 333 | 100.00% |
